Entropy Neurodynamics

Entropy Neurodynamics Operating Cash Flow

The Operating Cash Flow of Entropy Neurodynamics (ENP.AX) as of Oct 25, 2026 is -3.41 M AUD. In the previous year, Operating Cash Flow was -7.77 M AUD — a change of -56.17% (higher).

Operating Cash Flow

-3.41 MAUD

YoY

-56.17%

Last updated:

Operating Cash Flow of Entropy Neurodynamics is 2026 -3.41 M AUD. Operating Cash Flow of Entropy Neurodynamics was 2025 -7.77 M AUD. It decreases by -56.17% higher compared to the previous year.

The Entropy Neurodynamics Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2019
-2.18 M AUD
Jan 1, 2020
-6.72 M AUD
Jan 1, 2021
-7.89 M AUD
Jan 1, 2022
-8.59 M AUD
Jan 1, 2023
-4.03 M AUD
Jan 1, 2024
-6.00 M AUD
Jan 1, 2025
-7.77 M AUD
Jan 1, 2026
-3.41 M AUD
The Entropy Neurodynamics Operating Cash Flow history
YEAROperating Cash FlowYoY
-3.41 MAUD-56.17%
-7.77 MAUD+29.50%
-6.00 MAUD+49.04%
-4.03 MAUD-53.15%
-8.59 MAUD+8.96%
-7.89 MAUD+17.39%
-6.72 MAUD+207.55%
-2.18 MAUD+2,225.64%
-93,932.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Entropy Neurodynamics Stock analysis

What does Entropy Neurodynamics do? Entropy Neurodynamics Ltd develops and commercializes exosomes as therapeutic agents. The company holds intellectual property related to exosome technology and offers LEAP manufacturing, LOAD API loading, and EVPS tropism technologies. Pharmaceutical and biotechnology companies purchase these proprietary technologies to enhance their own exosome-based products. The firm invests in biopharmaceutical drug development and leverages its portfolio of know-how to support partners in exosome medicine development. Exopharm Ltd. is the company's brand name, and it operates through its exosome technology portfolio. The firm's technologies solve key challenges in exosome medicine success, including manufacturing efficiency and targeted delivery. Biopharmaceutical companies are the primary buyers of these technologies, seeking to integrate exosome delivery systems into their therapeutic pipelines. The company's business model centers on licensing its exosome-related IP and know-how to pharmaceutical and biotech firms. By providing LEAP, LOAD API, and EVPS technologies, Entropy Neurodynamics enables partners to overcome technical barriers in exosome-based drug development. This approach generates revenue through technology licensing agreements with industry partners. Entropy Neurodynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entropy Neurodynamics stock

Operating Cash Flow of Entropy Neurodynamics is -3.41 M AUD in 2026.

Operating Cash Flow of Entropy Neurodynamics changed from -7.77 M AUD to -3.41 M AUD, representing a -56.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Entropy Neurodynamics since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Entropy Neurodynamics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Entropy Neurodynamics

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Entropy Neurodynamics